Boston Therapeutics Ph 2 Study Achieves Full Enrollment
22. August 2019 13:55 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is again pleased to announce full enrollment of the BTI320 Ph 2 double-blind, placebo-controlled, multicenter...
Boston Therapeutics Announces Official Sales and Marketing Launch of Sugardown® in Asia
14. Februar 2019 11:18 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics...
Boston Therapeutics Announces Marketing of Sugardown® in Asia
13. Dezember 2018 11:13 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel...
Boston Therapeutics Announces Initiation of Sales of Sugardown® in Asia
07. Dezember 2018 13:26 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel...
Boston Therapeutics and Prevail InfoWorks Announce Strategic Clinical Partnership
03. Oktober 2018 08:15 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of carbohydrate based...
Boston Therapeutics Initiates New Exploratory and Adaptive Multicenter Clinical Study of BTI320 On Type 2 Diabetics Currently on Metformin and or Sulfonylureas in the United States
24. September 2018 11:35 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel...
Boston Therapeutics Phase IIa Study Results Accepted for Publication
24. August 2018 09:30 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Aug. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is pleased to announce the acceptance of the Phase IIa proof of concept study evaluating the efficacy and safety...
Boston Therapeutics to launch social commerce channel for Sugardown® in China
09. August 2018 11:52 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (“BTI”) (OTCQB:BTHE), a BioPharmaceutical leader in the design, development and commercialization of innovative...
Boston Therapeutics Introduces Sugardown® to the US under kathy Ireland® Health & Wellness
27. Juni 2018 12:52 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics...
Boston Therapeutics Initiates New Clinical Study of BTI-320
22. Mai 2018 12:58 ET
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics...